Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) EBITDA (2016 - 2025)

Historic EBITDA for Adma Biologics (ADMA) over the last 13 years, with Q3 2025 value amounting to $51.0 million.

  • Adma Biologics' EBITDA rose 2869.47% to $51.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $167.0 million, marking a year-over-year increase of 4536.48%. This contributed to the annual value of $139.0 million for FY2024, which is 54248.8% up from last year.
  • According to the latest figures from Q3 2025, Adma Biologics' EBITDA is $51.0 million, which was up 2869.47% from $42.8 million recorded in Q2 2025.
  • Over the past 5 years, Adma Biologics' EBITDA peaked at $51.0 million during Q3 2025, and registered a low of -$15.6 million during Q2 2021.
  • Moreover, its 5-year median value for EBITDA was -$473000.0 (2023), whereas its average is $10.1 million.
  • Per our database at Business Quant, Adma Biologics' EBITDA plummeted by 460.91% in 2021 and then skyrocketed by 838773.78% in 2024.
  • Over the past 5 years, Adma Biologics' EBITDA (Quarter) stood at -$13.2 million in 2021, then surged by 54.07% to -$6.1 million in 2022, then surged by 334.93% to $14.2 million in 2023, then skyrocketed by 169.25% to $38.3 million in 2024, then soared by 33.11% to $51.0 million in 2025.
  • Its last three reported values are $51.0 million in Q3 2025, $42.8 million for Q2 2025, and $34.9 million during Q1 2025.